Joanna Schwartz, Pharm.D., BCOP

Bio: 

Education

Board Certified Oncology Pharmacist (BCOP)
PGY1 residency and Oncology residency at the Hospital of the University of Pennsylvania, Philadelphia, PA
Pharm.D., Drake University College of Pharmacy, Des Moines, IA

Practice Site

Fletcher Allen Healthcare/University of Vermont Medical School, Vermont Cancer Center (Ambulatory Care Chemotherapy Infusion Clinic), Burlington, VT. 

Current Research Study

Randomized, blinded study of loratadine (Claritan) for the prevention and treatment of pegfilgrastim-induced bone pain.

Selected Publications

Schwartz J, To, J. A review of over-the-counter (OTC) agents available for mucositis and xerostomia. The Oncology Pharmacist, 2013, in press.  

Schwartz J, Natale J.  Value Based Cancer Care Online Pharmacist Continuing Education (CE). Improving Outcomes in the Management of Chemotherapy Induced Nausea and Vomiting. The pharmacists’ role. ACPE# 0468-9999-13-010-H01-P Valid through August 2014. http://www.lynxcme.com/cme/oncology/23-improving-outcomes-in-the-management-of-chemotherapy-induced-nausea-and-vomiting-the-pharmacist-s-role.  

Schwartz J. Hogan S. Prevention and Treatment of Hand-Foot Syndrome from Anti-VEGF Tyrosine Kinase Inhibitors. The Oncology Pharmacist, May 2013.  

Schwartz J. Schwartz,  Rowena, Kraft S. Guideline Updates for Health System Pharmacists: Focus on chemotherapy –induced nausea and vomiting (CINV). Value Based Cancer Care. Print supplement, March 2012.  

Schwartz J and Bottiglieri S. Cabazitaxel for metastatic prostate cancer. The American Journal of Lifestyle Medicine,  December 2012, 12(2).  

Schwartz J and Charpentier M. Bevacizumab (Avastin) for breast cancer. The Oncology Pharmacist. (Vol 12(1): October 2011.

Schwartz J and Charpentier M. Bevacizumab (Avastin) for breast cancer. The Oncology Nurse. (Vol 12(1): October 2011.  

Schwartz, J. Dexamethasone premedication for prophylaxis of taxane toxicities: can the doses be reduced when paclitaxel or docetaxel are given weekly? Journal of Oncology Pharmacy Practice, Vol 8(11).  J Oncol Pharm Prac, first published on August 1, 2011doi:10.1177/1078155211409473.

Schwartz, J. Novel Targeted Agents for Metastatic Breast Cancer. The Oncology Pharmacist. Vol 4 (1). Feb 2011.

Schwartz, J. New Treatments for Metastatic Breast Cancer. The Oncology Nurse. Vol 4 (1). Feb 2011.

Schwartz, J. Non-anthracycline chemotherapy regimens for the adjuvant treatment of early stage breast cancers. Formulary, Newsletter Edition, November 2010.

DS Dizon, A Stuckey, J Schwartz. Pegylated liposomal doxorubicin in recurrent serous carcinoma of the uterus. J Clin Oncol 2010; 27 (Suppl; abstr e16538).

Schwartz J.Current combination chemotherapy regimens for metastatic breast cancer. American Journal of Health-System Pharmacy.Vol. 66, Issue 23_Supplement_6, S3-S8, 2009

Schwartz J, Toste B, and Dizon D. Chemotherapy toxicity in gynecologic cancer patients with a BSA > 2 m2: The experience from the Program in Women’s Oncology/Brown Medical School. Gynecologic Oncology,.113; Vol 114, Iss 1, July 2009, p. 53-56.

McCourt C, Young M, Schwartz, J, Young W, DiSilvestro P, Brard L, Tejada-Berges T, Bradley A, Dizon, D. Factors associated with response to taxanes as a later-line treatment of recurrent ovarian cancer. International Journal of Gynecologic Cancer.19(3):343-347, April 2009.

Abellar R, Pepperell J, Greco D, Gundogan F, Kostanidov S, Schwartz J, Tantrahavi U, DePaepe M. Effects of Chemotherapy During Pregnancy on the Placenta. Pedia Devel Pathol. 2009 Mar 12(1):35 - 41.

Dizon D, Schwartz J, Kemeny N. Hepatic Arterial Infusion (HAI) of chemotherapy for the treatment of colorectal cancer liver metastases. Surg Oncol Clin N Am. 2008 (17): 759 - 71.

Schwartz, J, Bandera, C, Bradley A, Brard L, Legare R. Granai CO, Dizon, D. Does the Platinum-Free Interval Predict the Incidence or Severity of Hypersensitivity Reactions to Carboplatin? The Experience from Women and Infants’ Hospital. Gynecologic Oncology. 2007 (105): 81-83.

Dizon D, Schwartz J, Rojan A, et al. Cross-Sensitivity Between Paclitaxel and Docetaxel in a Women's Cancers' Program. Gynecologic Oncology. 2006 Jan;100(1):149-151.

Dizon D, Weitzen S, Rojan A, Schwartz J, et al. Two for Good Measure: Six versus Eight Cycles of Carboplatin and Paclitaxel as Adjuvant Treatment for Epithelial Ovarian Cancer. Gynecologic Oncology. 2006. Jan:100(2): 417-421.

Gordinier M, Dizon D, Fleming E, Weitzen S, Schwartz J, et al. Elevated Body Mass Index Does Not Increase the Risk of Palmar-Plantar Erythrodysesthesia in Patients Receiving Pegylated Liposomal Doxorubicin. Gynecologic Oncology. 2006 (103): 72-74.

Schwartz J, Domchek SM, Hwang WT, Fox K, et al. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Annals of Oncology. 2005 Feb;16(2):247-52.

Moderated Poster Presentations

Reversible Posterior Leukoencephalopathy Syndrome from anti-VEGF tyrosine kinase inhibitors (TKIs): A case report of axitinib and literature review. Ji, Yongli, Schwartz J, Yankulina O, Ades S. Northeast chapter of ASCO (NECOS), annual meeting, Oct 26th, Stowe, VT, 2013.
 
Chemotherapy toxicity in gynecologic cancer patients with a BSA > 2 m2: The experience from the Program in Women’s Oncology/Brown Medical School. Schwartz J, Toste B, and Dizon D. 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), 2008, Chicago, IL.
 
Factors associated with response to taxanes as a later-line treatment of recurrent ovarian cancer. McCourt C, Young M, Schwartz, J, Young W, DiSilvestro P, Brard L, Tejada-Berges T, Bradley A, Dizon D. 38th Annual Meeting of the Society of Gynecologic Oncologists, San Diego, CA, March 3-7, 2007.
 
Does the Platinum-free Interval Predict the Incidence or Severity of Hypersensitivity Reactions to  Carboplatin? The Experience from Women and Infants’ Hospital. Schwartz J and Dizon D. 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO), 2006, Atlanta, Georgia.
 
Cross-sensitivity between Paclitaxel and Docetaxel in a Women's Cancers Program. Schwartz J and Dizon D. 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). May 13-17, 2005. Orlando, Florida.
 
Differences in VEGF Receptor, Ang-1, Ang-2, Tie-2 mRNA Expression After Microvascular Fibrin Deposition in Human Cardiac Allografts. Schwartz J. 113th Session of the Iowa Academy of Science Meeting, April 2001, Des Moines, IA
 
Differences in VEGF Receptor, Ang-1, Ang-2, Tie-2 mRNA Expression After Microvascular Fibrin Deposition in Human Cardiac Allografts. Schwartz J,  23rd Annual Pharmacy Student Research Conference, April 2001, Morgantown, WV. Sponsored and travel grant provided by Merck Pharmaceutical Company.

Abstracts  

Dizon DS, Rojan A, Schwartz. J, et al. Cross-sensitivity between Paclitaxel and Docetaxel in a Women's Cancers Program. Abstract #:2052 Abstracts of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). May 13-17, 2005. Orlando, Florida, USA. (Part 2).  Journal of Clinical Oncology. 23(16 Suppl Pt 2):1090s-1100s, 2005 Jun 1.  

Torry RJ, Schwartz J, Hsu D, Miller S, Labarrere C, Torry D.  VEGF and VEGF Receptor Expression in Human Heart Tissue. J. Mol. Cell. Cardiol. 32(5):A70, 2000. Presented:  XXII Annual Scientific Sessions, International Society for Heart Research, Louisville, KY, June, 2000.  

Torry RJ, Snyder K, Schwartz J, Miller S, Helmreich J, Labarrere C. Quantitative Differences in VEGF Receptor mRNA Expression After Microvascular Fibrin Deposition in Human Cardiac Allografts. Presented: Experimental Biology 2001 Meetings, Orlando, FL, April, 2001.  

Schwartz J, Snyder K, Miller S, Helmreich C, Labarrere C, Torry RJ. Differences in VEGF Receptor, Ang-1, Ang-2 mRNA Expression After Microvascular Fibrin Deposition in Human Cardiac Allografts. Presented: 113th Session of the Iowa Academy of Science and Iowa Physiological Society, Des Moines, IA, May, 2001.  

Book Chapter  

Torry RJ, Schwartz J, Torry DS. Vascularization of the Placenta. In: Cardiovascular Molecular Morphogenesis: Assembly of the Vasculature and its Regulation.  RJ Tomanek, Ed. Springer-Verlag, New York, 2002.  

Reviewer

1) International Journal of Gynecologic Oncology
2) American Journal of Clinical Oncology
3) American Journal of Lifestyle Medicine  

Research Experience/Projects         

Ongoing: Loratadine for the treatment of pegfilgrastim-induced bone pain

Coinvestigator with Vermont Cancer Center (VCC/UVM) faculty: randomized, placebo-controlled, CALBG-grant funded study   

Primary investigator: Dr Steven Grunberg, co, investigator Joanna Schwartz, Farrah Khan, Julia Moukskarya          

Professional Organizations

President of the Vermont Society of Health-System Pharmacists (VTSHP) for 2011-2012

Faculty Advising

Faculty Advisor for the ACPHS-VT Campus Colleges Against Cancer and the Multicultural Club.

Assistant Professor
Department of Pharmacy Practice